Related Experiment Video
Updated: May 5, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population
Atika Mansoor1, Lubna Ali, Noor-ul Sabah
1Institute of Biomedical and Genetic Engineering, 24-Mauve area, G-9/1, Islamabad 44000, Pakistan. atikamansoor@hotmail.com.
Insights
Mutations in the NS5A region of Hepatitis C virus (HCV) genotype 3a, specifically downstream of PKRBD, may predict interferon therapy response. Younger patients showed better outcomes than older individuals.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Hepatitis C virus (HCV) causes liver cirrhosis and cancer, affecting 3% of the global population.
- Interferon therapy response in HCV is influenced by viral genotype and host factors.
- Genotype 3a patients often show incomplete response to interferon treatment.
Purpose of the Study:
- To investigate genetic variations in the NS5A region of HCV genotype 3a.
- To identify potential predictors of interferon therapy response in HCV-3a patients.
- To analyze the structural impact of observed mutations.
Main Methods:
- Sequencing of the NS5A region from responders (SVR) and non-responders (non-SVR) to interferon therapy.
- Comparison of mutations in the PKRBD and downstream regions of NS5A.
- Analysis of tertiary protein structure changes due to mutations.
- Comparison of patient age groups and treatment response.
Main Results:
- No significant difference in mutations within the PKRBD of NS5A between responders and non-responders.
- Two statistically significant mutations identified downstream of PKRBD at positions 2309 (Ala to Ser) and 2326 (Gly to Ala).
- Observed mutations led to notable changes in tertiary protein structure.
- Younger patients demonstrated a significantly better response to interferon therapy compared to older patients.
Conclusions:
- The NS5A region between PKRBD and IRRDR may be crucial for predicting interferon therapy response in HCV genotype 3a.
- ISDR and PKRBD regions did not show involvement in treatment response.
- Further functional studies are needed to elucidate the role of NS5A region variations in HCV-3a interferon treatment outcomes.
Background:
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma and infects about 3% world population. Response to interferon therapy depends upon the genotype of the virus and factors associated with the host. Despite a good response to interferon therapy, a considerable number of genotype 3a infected patients remains unalleviated.
Results:
In total forty-nine patients including twenty-five non-responders (non-SVR) and twenty-four responders (SVR) were recruited. Patients were tested for viral status at different intervals and the isolated RNA was sequenced for the NS5A region in both groups. The comparison of PKRBD of HCV between the SVR and non-SVR patients did not confirm any significant difference in the number of mutations. However, when the sequence downstream to the PKRBD of NS5A was compared, two important statistically significant mutations were observed; at positions 2309 (Ala to Ser) and 2326 (Gly to Ala). These mutations were then analysed for tertiary protein structure and important structural changes were observed. Statistically significant difference was also observed when age groups of patients were compared; younger patients showed better response than the older ones.
Conclusions:
The region between PKRBD and IRRDR may be important for prediction of response to IFN therapy for genotype 3a. ISDR and PKRBD have not shown any involvement in treatment response. Further functional analyses of these findings can help in understanding the involvement of the NS5A region in interferon treatment of HCV-3a infected patients.
Related Concept Videos
01:28Viral Hepatitis I: Introduction
01:25Hepatitis
01:30Inhibitors of Viral Protein Synthesis
01:27Cytomegalovirus Disease